• News & Themen

  • Publikationen im Forschungsschwerpunkt „Zelldynamik und Bildgebung“

    2022

    Bäumer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, Geyer C, Grunert K, Kellmann N, Peipp M, Kailayangiri S, Gutierrez Suburu ME, Strassert CA, Schenk M, Greune L, Rüter C, Dersch P, Hartmann W, Rossig C, Neri D, Müller-Tidow C, Schwöppe C, Schliemann C, Khandanpour C, Lenz G, Berdel WE, Bäumer S. Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J Hematol Oncol 2022;15Abstract
    Baumer N, Tiemann J, Scheller A, Meyer T, Wittmann L, Suburu MEG, Greune L, Peipp M, Kellmann N, Gumnior A, Brand C, Hartmann W, Rossig C, Muller-Tidow C, Neri D, Strassert CA, Ruter C, Dersch P, Lenz G, Koeffler HP, Berdel WE, Baumer S. Targeted siRNA nanocarrier: a platform technology for cancer treatment. Oncogene 2022;41: 2210-2224. Abstract

    2021

    Schliemann C, Kessler T, Berdel AF, Hemmerle T, Angenendt L, Altvater B, Rossig C, Mikesch J-H, Lenz G, Schafers M, Neri D, Stelljes M, Berdel WE. Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. Br J Haematol 2021;192: e148-e151. Abstract

    2019

    Kailayangiri S, Altvater B, Lesch S, Balbach S, Gottlich C, Kuhnemundt J, Mikesch J-H, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Muller I, Walles H, Hartmann W, Rossig C. EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. Mol Ther 2019;27: 933-946. Abstract

    2018

    Rossig C, Kailayangiri S, Jamitzky S, Altvater B. Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. Front Oncol 2018;8: 513. Abstract
    Spurny C, Kailayangiri S, Altvater B, Jamitzky S, Hartmann W, Wardelmann E, Ranft A, Dirksen U, Amler S, Hardes J, Fluegge M, Meltzer J, Farwick N, Greune L, Rossig C. T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. Oncotarget 2018;9: 6536-6549. Abstract
    Spurny C, Kailayangiri S, Jamitzky S, Altvater B, Wardelmann E, Dirksen U, Hardes J, Hartmann W, Rossig C. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. Pediatr Blood Cancer 2018;65: e26719. Abstract

    2016

    Baumer N, Appel N, Terheyden L, Buchholz F, Rossig C, Muller-Tidow C, Berdel WE, Baumer S. Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. Nat Protoc 2016;11: 22-36. Abstract
    Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. OncoImmunology 2016: e1250050. Abstract

    2015

    Agelopoulos K, Richter GHS, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein H-U, Kontny U, Dugas M, Poos K, Korsching E, Buch T, Weckesser M, Schulze I, Besoke R, Witten A, Stoll M, Kohler G, Hartmann W, Wardelmann E, Rossig C, Baumhoer D, Jurgens H, Burdach S, Berdel WE, Muller-Tidow C. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. Clin Cancer Res 2015;21: 4935-4946. Abstract
    Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schafers M, Altvater B, Rossig C, Grunewald I, Wardelmann E, Kohler G, Neri D, Stelljes M, Berdel WE. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Res 2015;3: 547-556. Abstract

    2014

    Altvater B, Kailayangiri S, Theimann N, Ahlmann M, Farwick N, Chen C, Pscherer S, Neumann I, Mrachatz G, Hansmeier A, Hardes J, Gosheger G, Juergens H, Rossig C. Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals. Cancer Immunol Immunother 2014;63: 1047-1060. Abstract

    2013

    Liebsch L, Kailayangiri S, Beck L, Altvater B, Koch R, Dierkes C, Hotfilder M, Nagelmann N, Faber C, Kooijman H, Ring J, Vieth V, Rossig C. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer 2013;109: 658-666. Abstract
    Lustfeld I, Altvater B, Ahlmann M, Ligges S, Brinkrolf P, Rosemann A, Moericke A, Rossig C. High Proportions of CD4+ T Cells among Residual Bone Marrow T Cells in Childhood Acute Lymphoblastic Leukemia Are Associated with Favorable Early Responses. Acta Haematol 2013;131: 28-36. Abstract
    Mueller S-K, Altvater B, Chen C, Kailayangiri S, Ahlmann M, Dirksen U, Juergens H, Rossig C. Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells. Oncol Rep 2013;29: 2348-2354. Abstract
    Rettinger E, Bonig H, Wehner S, Lucchini G, Willasch A, Jarisch A, Soerensen J, Esser R, Rossig C, Klingebiel T, Bader P. Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant 2013;48: 1141-1143. Abstract
    Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013;152: 1065-1076. Abstract